Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
108 participants
OBSERVATIONAL
2014-04-30
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Cerebral Edema in Children Having Diabetic Ketoacidosis
NCT02937441
Clinical and Laboratory Parameters Associated With Different Degrees of Dehydration Among Children With Diabetic Ketoacidosis
NCT05383404
Diabetic Ketoacidosis Diagnosis and Management
NCT06327737
Diabetic Ketoacidosis: Brain Morphology and Cognition
NCT02443415
Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)
NCT00970567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cerebral edema (CE), or "brain swelling," can also occur with severe DKA. It is unclear what causes CE in children with DKA. Proposed mechanisms include changes in blood flow to the brain, inflammatory mediation, and alteration in the intracellular and extracellular fluid composition in the brain. CE can be "clinically apparent" or "subclinical" in terms of symptomatology. Children with clinically apparent DKA-related CE present with neurologic deficits and altered mental status. These children are at risk for herniation of the brain stem due to elevated pressures in and around the brain, and ultimately death. The neurologic manifestations of clinically apparent DKA-related CE typically occur 4-12 hours after the initiation of medical therapy. However, cases have been reported to occur prior to initiation of therapy. Although clinically apparent DKA-related CE is rare, occurring in 0.5-1% of children with DKA, subclinical DKA-related CE is much more common with estimates suggesting that up to 54% of children with DKA have underlying CE that goes clinically undetected. Early identification of both clinically apparent and subclinical DKA-related CE is critical as the time between initial neurologic symptoms and clinical deterioration can be as little as 3 hours. Moreover, early identification of subclinical DKA-related CE may lead to differences in medical therapy.
Current evaluation for DKA-related CE necessitates a high index of clinical suspicion and often times such patients receive advanced brain imaging such as computed tomography (CT) scans. While CT scans can identify CE, this imaging modality exposes patients to ionizing radiation, is expensive, and may take considerable time in some instances. Moreover, CE can occur in the absence of acute change on CT and some patients with subclinical CE may go unidentified. Magnetic resonance imaging (MRI) has been used to identify subclinical DKA-related CE, however this is often time-consuming, expensive, requires sedation, or may be unavailable at some centers. Ocular sonography (ultrasound) is an alternative imaging technique that can provide immediate diagnostic capability at the bedside and minimize radiation exposure. This technique has been used to rapidly and accurately detect increased brain swelling through measurement of the optic nerve sheath diameter (ONSD) in a number of clinical situations including pediatric head trauma, hydrocephalus and ventriculoperitoneal shunt malfunctions, and altitude sickness in adults.
It is believed, no study has used ocular ultrasound to examine the ONSD in the setting of diabetes or DKA for identification of clinically apparent or subclinical CE. It is unclear if patients with T1DM have a fundamentally different baseline ONSD measurement compared to described normal values. It is also unclear how the ONSD varies during times of diabetes-related illness, such as high blood glucose levels without criteria for DKA compared to unequivocal DKA.
Investigators plan to conduct a prospective study including children aged 7-18 years that present to the Children's Endocrinology Clinic and Children's Emergency Department. The objective of this study is to assess the utility of sonographic measurements of the ONSD as a tool for identification of DKA-related CE. Specifically, the primary aim of this study is to measure and compare the mean ONSD in children with well-controlled T1DM to those presenting to the Emergency Department (ED) with DKA and to those presenting to the ED with T1DM and hyperglycemia without criteria for DKA. Investigators hypothesize that the mean ONSD measurement is smaller in children with well-controlled T1DM compared to children presenting to the ED with DKA and compared to children with T1DM and hyperglycemia without criteria for DKA. Secondarily, investigators aim to compare the mean ONSD in children presenting to the ED with DKA to those presenting to the ED with T1DM and hyperglycemia without criteria for DKA. The study team hypothesizes that the mean ONSD measurement is larger in children presenting to the ED with DKA compared children presenting with T1DM and hyperglycemia without criteria for DKA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ED T1DM and hyperglycemia without criteria for DKA
No interventions assigned to this group
Well controlled T1DM
No interventions assigned to this group
ED DKA
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
DKA group recruited from Children's ED. Criteria for DKA:
1. Hyperglycemia \>200 mg/dL AND
2. Venous pH \<7.30 AND/OR
3. Bicarbonate level \<15 AND
4. Either positive urine or serum ketones
T1DM and hyperglycemia without criteria for DKA (recruited from Children's ED). Criteria for inclusion:
1\. Hyperglycemia (\>200 mg/dL) not meeting above criteria for DKA
Well-controlled T1DM control group (recruited from Children's Endocrinology Clinic). Criteria for inclusion:
1. Hemoglobin A1c \<8% at time of clinic visit
2. No previous episodes of DKA other than at the time of diagnosis
3. Has never had a documented hemoglobin A1c \>10%
Exclusion Criteria
1. Treatment with more than 10 mL/kg IV fluids prior to transfer from outside hospital
2. Treatment with insulin prior to transfer from outside hospital
3. Patients with type 2 DM
4. Patients with Hyperosmolar Hyperglycemic Nonketotic State
5. Underlying neurologic condition predisposing to changes in ICP (hydrocephalus, ventriculoperitoneal shunt, Chiari I malformation, Chiari II malformation, pseudotumor cerebri, brain tumor)
6. Underlying condition predisposing to changes in intraocular pressure (glaucoma, eye trauma)
Well-controlled T1DM group with poorly controlled disease, defined as:
1. Hemoglobin A1c \>8% OR
2. \>1 previous episode of DKA, including DKA at time of diagnosis OR
3. Hemoglobin A1c documented \>10% any time in the past
7 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospitals and Clinics of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kelly Bergmann, MS, DO
Role: PRINCIPAL_INVESTIGATOR
Children's Hospitals and Clinics of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospitals and Clinics of Minnesota
Minneapolis and Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1402-020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.